Organon & Co. (OGN) Q3 2022 Earnings Call Transcript

Nov. 03, 2022 12:17 PM ETOrganon & Co. (OGN)
SA Transcripts profile picture
SA Transcripts

Organon & Co. (NYSE:OGN) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET

Company Participants

Jennifer Halchak – Vice President, Investor Relations

Kevin Ali – Chief Executive Officer

Matt Walsh – Chief Financial Officer

Sandra Milligan – Head of R&D

Conference Call Participants

Terence Flynn – Morgan Stanley

Umer Raffat – Evercore ISI

David Amsellem – Piper Sandler

Jason Gerberry – BofA

Greg Fraser – Truist Securities


Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Third Quarter 2022 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question- and-answer session. [Operator Instructions] As a reminder, this call is being recorded. Thank you.

I would like now to turn the call over to Jennifer Halchak, Vice President, Investor Relations. Please begin your conference.

Jennifer Halchak

Thank you, Michele. Good morning everyone and thank you for joining Organon's third quarter 2022 earnings call. With me today are Kevin Ali, Organon's Chief Executive Officer; and Matt Walsh, our Chief Financial Officer; Dr. Sandra Milligan, Organon's Head of R&D, will also be joining us for the Q&A portion of this call. Today, we'll be referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events & Presentations section of our Organon Investor Relations website at

Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings with

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.